Protia: 1Q26 Sales +41.8%, Operating Profit +84.4% YoY – Strong Performance Continues

1Q26 Revenue KRW 3.82bn (+41.8% YoY), Operating Profit KRW 0.76bn (+84.4%), Net Profit KRW 0.98bn (+37.0%)
Debt ratio 7.7%, very sound financial structure, Total Equity KRW 31.69bn
Overseas sales KRW 1.72bn (45.1% of total), +24.9% YoY
R&D expense KRW 0.66bn (17.4% of sales), net of government grants KRW 0.12bn
New products launched: PROTIA Allergy-Q 192D, Q-AST 192 Pro, IMSAFE Saliva
Holds PLA technology for allergy multiplex diagnostics and capacitance-based antibiotic susceptibility testing
Past sanctions: medical device law violation (fine KRW 3mn in 2022), delayed large shareholding report (warning in 2023)
Accumulated deficit KRW 12.49bn; no dividend possible